S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in

Bicycle Therapeutics Stock Forecast, Price & News

+1.29 (+5.34 %)
(As of 02/24/2021 12:00 AM ET)
Today's Range
Now: $25.45
50-Day Range
MA: $26.02
52-Week Range
Now: $25.45
Volume1.31 million shs
Average Volume188,994 shs
Market Capitalization$542.21 million
P/E RatioN/A
Dividend YieldN/A
Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BCYC
Year FoundedN/A



Sales & Book Value

Annual Sales$13.80 million
Book Value$5.27 per share


Net Income$-30,610,000.00
Net Margins-321.26%


Market Cap$542.21 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.35 out of 5 stars

Medical Sector

623rd out of 1,958 stocks

Pharmaceutical Preparations Industry

318th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
+1.29 (+5.34 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BCYC News and Ratings via Email

Sign-up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Bicycle Therapeutics (NASDAQ:BCYC) Frequently Asked Questions

Is Bicycle Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Bicycle Therapeutics stock.
View analyst ratings for Bicycle Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Bicycle Therapeutics?

Wall Street analysts have given Bicycle Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bicycle Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Bicycle Therapeutics' next earnings date?

Bicycle Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Bicycle Therapeutics

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics plc (NASDAQ:BCYC) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($0.52) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.52). The company had revenue of $3.84 million for the quarter, compared to the consensus estimate of $1.05 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 42.73% and a negative net margin of 321.26%.
View Bicycle Therapeutics' earnings history

How has Bicycle Therapeutics' stock price been impacted by Coronavirus?

Bicycle Therapeutics' stock was trading at $17.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BCYC stock has increased by 43.8% and is now trading at $25.45.
View which stocks have been most impacted by COVID-19

What price target have analysts set for BCYC?

4 Wall Street analysts have issued 12-month target prices for Bicycle Therapeutics' shares. Their forecasts range from $25.00 to $58.00. On average, they expect Bicycle Therapeutics' stock price to reach $38.00 in the next year. This suggests a possible upside of 49.3% from the stock's current price.
View analysts' price targets for Bicycle Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Bicycle Therapeutics' key executives?

Bicycle Therapeutics' management team includes the following people:
  • Kevin Lee, Chief Executive Officer & Director
  • Lee H. Kalowski, President, Chief Financial & Accounting Officer
  • Michael Skynner, Chief Operating Officer
  • Nicholas Keen, Chief Scientific Officer
  • Dominic Smethurst, Chief Medical Officer

Who are some of Bicycle Therapeutics' key competitors?

What other stocks do shareholders of Bicycle Therapeutics own?

When did Bicycle Therapeutics IPO?

(BCYC) raised $64 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Bicycle Therapeutics' stock symbol?

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

Who are Bicycle Therapeutics' major shareholders?

Bicycle Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Atlas Venture Advisors Inc. (3.46%), Victory Capital Management Inc. (0.96%), Renaissance Technologies LLC (0.46%), Verition Fund Management LLC (0.19%), Bank of New York Mellon Corp (0.07%) and US Bancorp DE (0.07%). Company insiders that own Bicycle Therapeutics stock include Deborah Harland, Kevin Lee, Lee Kalowski, Life Sciences Fund V Lp Sv and Plc Glaxosmithkline.
View institutional ownership trends for Bicycle Therapeutics

Which major investors are selling Bicycle Therapeutics stock?

BCYC stock was sold by a variety of institutional investors in the last quarter, including Atlas Venture Advisors Inc.. Company insiders that have sold Bicycle Therapeutics company stock in the last year include Kevin Lee, Lee Kalowski, and Plc Glaxosmithkline.
View insider buying and selling activity for Bicycle Therapeutics
or view top insider-selling stocks.

Which major investors are buying Bicycle Therapeutics stock?

BCYC stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Victory Capital Management Inc., Bank of New York Mellon Corp, US Bancorp DE, Captrust Financial Advisors, and Verition Fund Management LLC. Company insiders that have bought Bicycle Therapeutics stock in the last two years include Deborah Harland, and Life Sciences Fund V Lp Sv.
View insider buying and selling activity for Bicycle Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bicycle Therapeutics' stock price today?

One share of BCYC stock can currently be purchased for approximately $25.45.

How much money does Bicycle Therapeutics make?

Bicycle Therapeutics has a market capitalization of $542.21 million and generates $13.80 million in revenue each year. The company earns $-30,610,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis.

How many employees does Bicycle Therapeutics have?

Bicycle Therapeutics employs 81 workers across the globe.

What is Bicycle Therapeutics' official website?

The official website for Bicycle Therapeutics is www.bicycletherapeutics.com.

Where are Bicycle Therapeutics' headquarters?

Bicycle Therapeutics is headquartered at B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT.

How can I contact Bicycle Therapeutics?

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company can be reached via phone at 441223261503.

This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.